In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Michael Diamond(Washington University in St. Louis), Andrianus Boon, Tamarand L. Darling(Washington University in St. Louis), Ishmael D. Aziati(Washington University in St. Louis), Xuping Xie(The University of Texas Medical Branch at Galveston), Spencer Stumpf(Washington University in St. Louis), Swathi Shrihari(Washington University in St. Louis), Ali H. Ellebedy(Washington University in St. Louis), Lisa A. Purcell, Scott A. Handley(Washington University in St. Louis), Pavlo Gilchuk(Vanderbilt University Medical Center), Laura A. VanBlargan(Washington University in St. Louis), James Brett Case(Washington University in St. Louis), Charles Y. Chiu(University of California, San Francisco), Miguel Garcia-Knight(University of California, San Francisco), Zhuoming Liu(Washington University in St. Louis), Traci L. Bricker(Washington University in St. Louis), James E. Crowe(Vanderbilt University Medical Center), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Lindsay Droit(Washington University in St. Louis), Daved H. Fremont(Washington University in St. Louis), John M. Errico(Washington University in St. Louis), Astha Joshi(Washington University in St. Louis), W. Blaine Stine(Emory University), Seth J. Zost(Vanderbilt University Medical Center), Sean P. J. Whelan(University of Pittsburgh Medical Center), Rita Chen, David Wang(Washington University in St. Louis), Baoling Ying(Washington University in St. Louis), Davide Corti(Vir Biotechnology (Switzerland)), Emma S. Winkler(Washington University in St. Louis), Raul Andino(University of California, San Francisco)
Research Square
April 23, 2021
Cited by 31


Related Papers